The dispute over the patent of CRISPR/Cas9: Chinese patent was not awarded to Zhang Feng

The patent battle for “Genetic Devil” CRISPR/Cas9 technology has made new progress. Despite the loss in the United States earlier this year, the European Patent Office and the UK Patent Office said that the University of California at Berkeley will receive a wide range of patents for CRISPR/Cas9 technology. Today, the University of California at Berkeley will win another point from China.

On June 19th, US time and Swiss time, Intellia Therapeutics and CRISPR Therapeutics announced that they have obtained patents on CRISPR gene editing technology granted by the State Intellectual Property Office of China.

CRISPR/Cas9专利之争:中国专利没授予张锋

From left to right: Dudna, Carpentier and Zhang Feng

Intellia Therapeutics and CRISPR Therapeutics have reported that they have obtained patents on CRISPR gene editing technology granted by the State Intellectual Property Office of China.

CRISPR/Cas9专利之争:中国专利没授予张锋

CRISPR/Cas9专利之争:中国专利没授予张锋

CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China

The co-founders of the two companies include Jennifer Doudna, a biologist at the University of California at Berkeley, and Emmanuelle Charpentier, a French microbiologist. In 2012, the two were the first to report that CRISPR technology can precisely cleave the DNA of bacteria (prokaryotic cells) in vitro.

According to news published by the two companies, the patent coverage granted in China uses the CRISPR/Cas9 single-guide gene editing technology to modify target DNA in both cellular and non-cellular environments, including the more core – for vertebrates such as humans or Modifications of other mammalian cells also involve the use of CRISPR technology to produce drugs for the treatment of disease.

In the United States, the patent for the use of CRISPR in eukaryotic cells or any cell-nuclear species belongs to the Broad Institute, a Chinese scientist, Zhang Feng. In 2013, only about half a year after the papers of Dudna and Carpentier, Zhang Feng team reported the first editing of CRISPR genes on human cells (eukaryotic cells).

Plant based protein

The so-called plant-based is the substitution of plant protein for animal protein food grade applications. Plant-based ingredients protein products come from plants such as soy, wheat and peas. That is pea protein powder, soy protein powder, pumpkin protein and so on. The plant protein application category includes protein drinks, dairy substitutes, meat substitutes, protein bars, nutritional supplements, processed meat, poultry and seafood, baking, food and sports nutrition products. Plant protein applications enhance the nutritional and functional properties of products, such as texture, emulsifying properties, solubility, stability and adhesion.

Hemp Seed Protein,Plant Protein,Pea Protein Powder,Rice Protein Powder,Enzymolysis Oat Powder

Xi'an Gawen Biotechnology Co., Ltd , https://www.amulyn-bio.com

Posted on